Senti Biosciences Inc
Company Profile
Business description
Senti Biosciences Inc is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Contact
2 Corporate Drive
First Floor
South San FranciscoCA94080
USAT: +1 650 239-2030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
39
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,209.33 | 26.38 | -0.32% |
| DAX 40 | 24,258.02 | 12.85 | -0.05% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,497.87 | 0.22 | -0.00% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |